Holen Sie sich die Stockscreener-App
0.6353
3.27%
0.0202
Schlusskurs vom Vortag:
$0.6151
Offen:
$0.62
24-Stunden-Volumen:
475.79K
Relative Volume:
0.41
Marktkapitalisierung:
$105.49M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-274.18M
KGV:
-0.2506
EPS:
-2.5346
Netto-Cashflow:
$-198.33M
1W Leistung:
-0.53%
1M Leistung:
-3.17%
6M Leistung:
-94.14%
1J Leistung:
-93.43%
1-Tages-Spanne:
$0.6161
$0.6364
1-Wochen-Bereich:
$0.611
$0.7697
52-Wochen-Spanne:
$0.611
$17.19
Neumora Therapeutics Inc Stock (NMRA) Company Profile
Firmenname
Neumora Therapeutics Inc
Sektor
Branche
Telefon
(857) 760-0900
Adresse
490 ARSENAL WAY, SUITE 200, WATERTOWN
Vergleichen Sie NMRA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NMRA
Neumora Therapeutics Inc
|
0.6353 | 105.49M | 0 | -274.18M | -198.33M | -2.5346 |
|
VRTX
Vertex Pharmaceuticals Inc
|
432.52 | 111.66B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
582.89 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
557.00 | 38.04B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
283.91 | 36.06B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
224.32 | 25.10B | 3.81B | -644.79M | -669.77M | -6.24 |
Neumora Therapeutics Inc Stock (NMRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-02 | Herabstufung | BofA Securities | Buy → Underperform |
| 2025-03-10 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-03-07 | Herabstufung | Guggenheim | Buy → Neutral |
| 2025-03-07 | Herabstufung | Stifel | Buy → Hold |
| 2025-01-02 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-11-05 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-10-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-07-22 | Eingeleitet | Needham | Buy |
| 2024-07-08 | Eingeleitet | Mizuho | Outperform |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Hold |
| 2023-10-10 | Eingeleitet | BofA Securities | Buy |
| 2023-10-10 | Eingeleitet | Guggenheim | Buy |
| 2023-10-10 | Eingeleitet | JP Morgan | Overweight |
| 2023-10-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-10-10 | Eingeleitet | Stifel | Buy |
| 2023-10-10 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Neumora Therapeutics Inc Aktie (NMRA) Neueste Nachrichten
Needham & Company LLC Reiterates "Buy" Rating for Neumora Therapeutics (NASDAQ:NMRA) - MarketBeat
Neumora Therapeutics (NASDAQ:NMRA) Posts Earnings Results, Misses Expectations By $0.02 EPS - MarketBeat
Kuehn Law Encourages Investors of Neumora Therapeutics, Inc. to Contact Law Firm - PR Newswire
Neumora Therapeutics, Inc.: Strengthened Financial Position and Strategic Operational Enhancements Drive Buy Rating - TipRanks
Neumora Therapeutics Venture Debt Facility - Leerink Partners
Neumora Therapeutics Reports Q1 2025 Financial Results - TipRanks
Earnings call transcript: Neumora Therapeutics Q1 2025 Sees Net Loss, Stock Rises - Investing.com
Neumora Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - The Manila Times
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives Average Rating of "Hold" from Brokerages - MarketBeat
Will Neumora Therapeutics (NASDAQ:NMRA) Spend Its Cash Wisely? - Yahoo Finance
Neumora Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Neumora Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 7, 2025NMRA - ACCESS Newswire
Neumora Therapeutics (NMRA) Expected to Announce Earnings on Monday - Defense World
Neumora Therapeutics Inc (NASDAQ: NMRA): What Matters Now - Stocksregister
Schonfeld Strategic Advisors LLC Buys 381,676 Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) - MarketBeat
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Average Rating of “Hold” by Analysts - Defense World
Investigation announced for Long-Term Investors in shares - openPR.com
Neumora Therapeutics (NMRA) Projected to Post Quarterly Earnings on Monday - MarketBeat
Invesco Ltd. Raises Holdings in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - Defense World
NMRA STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - NatLawReview.com
Nothing is Better Than Neumora Therapeutics Inc (NMRA) stock at the moment - Sete News
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Stock Position Increased by Wells Fargo & Company MN - Defense World
Should investors be concerned about Neumora Therapeutics Inc (NMRA)? - uspostnews.com
NMRA stock rated an Underperform by BofA Securities - knoxdaily.com
Wainwright maintains $18 target on Neumora Therapeutics stock By Investing.com - Investing.com Canada
Neumora Therapeutics (NASDAQ:NMRA) versus Big Cypress Acquisition (OTCMKTS:BCYP) Head to Head Comparison - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Legal & General Group Plc Buys 50,289 Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) - The AM Reporter
Neumora Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025 - Yahoo Finance
Investors Who Lost Money on Neumora Therapeutics, Inc. (NMRA) Should Contact Levi & Korsinsky About Pending Class ActionNMRA - ACCESS Newswire
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Shares Bought by Capital International Investors - MarketBeat
It is Poised to be a Bull Market for Neumora Therapeutics Inc (NMRA) - Sete News
NMRA Stock Sees Surge of Approximately 8.37% in Last Five Days - knoxdaily.com
NMRA’s valuation metrics: A comprehensive analysis - uspostnews.com
Former Neumora CEO to lead Galapagos spinout - BioPharma Dive
Franklin Resources Inc. Sells 44,345 Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) - Defense World
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives $9.29 Consensus PT from Analysts - MarketBeat
Alliancebernstein L.P. Sells 22,930 Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) - Defense World
Neumora Therapeutics (NASDAQ:NMRA) Receives Buy Rating from Needham & Company LLC - MarketBeat
Vanguard Group Inc. Purchases 195,142 Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) - Defense World
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Consensus Rating of “Hold” by Analysts - Defense World
Needham & Company LLC Reaffirms “Buy” Rating for Neumora Therapeutics (NASDAQ:NMRA) - Defense World
KLP Kapitalforvaltning AS Makes New Investment in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - Defense World
Neumora Therapeutics, Inc.: Strategic Advancements and Optimism Drive Buy Rating - TipRanks
Finanzdaten der Neumora Therapeutics Inc-Aktie (NMRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Neumora Therapeutics Inc-Aktie (NMRA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| BERNS PAUL L | See Remarks |
Feb 18 '25 |
Sale |
1.69 |
13,871 |
23,468 |
7,405,004 |
| Milligan Michael Lee | See Remarks |
Feb 18 '25 |
Sale |
1.69 |
1,978 |
3,351 |
22,470 |
| Aurora Daljit Singh | Chief Strategy Officer |
Feb 18 '25 |
Sale |
1.68 |
8,565 |
14,347 |
88,935 |
| Lenz Robert A. | Head of R&D |
Feb 18 '25 |
Sale |
1.67 |
5,614 |
9,383 |
309,092 |
| Pinto Joshua | President |
Feb 18 '25 |
Sale |
1.67 |
8,048 |
13,477 |
76,952 |
1.82%
0.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):